Antiphospholipid syndrome treatment beyond anticoagulation: Are we there yet?

Lupus

Volumn 19, Issue 4, 2010, Pages 475-485

  Pierangeli, S S ^a   Erkan, D ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

Anticardiolipin antibodies; Antiphospholipid antibodies; Endothelial cells; Lupus anticoagulant; Targeted therapies; Thrombosis

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ATORVASTATIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CAPTOPRIL; CERIVASTATIN; DEFIBROTIDE; DILAZEP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR; FLUINDOSTATIN; HEPARIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; PENTOXIFYLLINE; PHOSPHOLIPID ANTIBODY; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THROMBOPLASTIN; UNINDEXED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOPATHOGENESIS; ISCHEMIC HEART DISEASE; NONHUMAN; PERINATAL MORBIDITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL; THROMBOSIS; UPREGULATION; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; DRUG DELIVERY SYSTEMS; FEMALE; HEPARIN; HUMANS; IMMUNOLOGIC FACTORS; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS; WARFARIN;

EID: 77951229587     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310361489     Document Type: Review

References (94)

1. Miyakis S., Lockshin MD, Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 ; 4: 295-306.
2. Erkan D., Harrison M., Levy R., et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007 ; 56: 2382-2391. (Pubitemid 47173586)
3. Fischetti F., Durigutto P., Pellis V., et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005 ; 106: 2340-2346. (Pubitemid 41510805)
4. Meroni PL, Raschi E., Carrera M., et al. Endothelia activation of aPL; a potential pathogenic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000 ; 15: 237-240.
5. Amengual O., Atsumi T., Khamashta M., et al. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998 ; 79: 276-281. (Pubitemid 28065869)
6. Cuadrado MJ, Buendia P., Velasco F., et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 2006 ; 4: 2461-2469. (Pubitemid 44575442)
7. Zhou H., Wolberg AS, Roubey AS Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004 ; 15: 2353-2358. (Pubitemid 39331833)
8. Forastiero RR, Martinuzzo ME, de Larranaga GF Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus 2005 ; 14: 129-136.
9. Forastiero RR, Martinuzzo ME, Broze GJ High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J Thromb Haemost 2003 ; 1: 718-724.
10. Williams FMK, Parmar K., Hughes GRV, Hunt BJ Systemic endothelial cell markers in primary antiphospholipid syndrome. J Thromb Haemost 2000 ; 84: 742-746.
11. de Prost D. Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells. J Cardiovasc Pharmacol 1995 ; 25 (Suppl 2). S114 - S118. (Pubitemid 26086258)
12. Burcoglu-ORal A., Erkan D., Asherson RA Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol 2002 ; 29: 2006-2011. (Pubitemid 34988713)
13. Napoleone E., Di Santo A., Camera M., et al. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 2000 ; 86: 139-143. (Pubitemid 30086173)
14. Espinola RG, Liu X., Colden-Stanfield M., et al. E-Selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2003 ; 1: 843-848.
15. Dunoyer-Geindre S., de Moerloose P., Galve-de Rochemonteiz B., et al. NF-κB is an essential intermediate in the activation of endothelial cells by anti-β2glycoprotein I antibodies. Thromb Haemost 2002 ; 88: 851-857. (Pubitemid 35345346)
16. Bohgaki M., Atsumi T., Yamashita Y., et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-b2Glycoprotein I antibodies. Int Immunol 2004 ; 16: 1633-1641. (Pubitemid 39480782)
17. Vega-Ostertag ME, Harris EN, Pierangeli SS Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004 ; 50: 2911-2919.
18. Vega-Ostertag ME, Carper K., Swerlick R., et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005 ; 52: 1545-1554. (Pubitemid 40663946)
19. Simoncini S., Sapet C., Camoin-Jau L., et al. Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome. Int Immunol 2004 ; 17: 489-500. (Pubitemid 40568124)
20. Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z., et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost 2007 ; 5: 1828-1834. (Pubitemid 47288938)
21. Montiel-Manzano G., Romay-Penabad Z., Papalardo de Martinez E., et al. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. Ann NY Acad Sci 2007 ; 1108: 540-553. (Pubitemid 47528768)
22. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002 ; 87: 518-522.
23. Pierangeli SS, Vega-Ostertag M., Gonzalez EB New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Expert Rev Mol Med 2007 ; 9: 1-15. (Pubitemid 350154117)
24. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001 ; 103: 276-283. (Pubitemid 32095415)
25. Jiménez S., Tassies D., Espinosa G., et al. Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus. Ann Rheum Dis 2008 ; 67: 835-840. (Pubitemid 351829385)
26. Straub A., Wendel HP, Azevedo R., Ziemer G. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation. Eur J Cardiothorac Surg 2005 ; 27: 617-621. (Pubitemid 40409733)
27. Jancinova V., Nosal R., Petrikova M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res 1994 ; 74: 495-504. (Pubitemid 24173331)
28. Lombard-Platlet S., Bertolino P., Deng H., Gerlier D., Rabourdin-Combe C. Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T cell. Immunology 1993 ; 80: 566-573. (Pubitemid 24010116)
29. Goldman FD, Gilman AL, Hollenback C., et al. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000 ; 95: 3460-3466. (Pubitemid 30428477)
30. Pierangeli SS, Vega-Ostertag M., Harris EN Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res 2004 ; 114: 467-476. (Pubitemid 39429425)
31. Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008 ; 112: 1687-1695.
32. Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2009 ; ([Epub ahead of print]).
33. Johnson R., Charnley J. Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin Orthop Relat Res 1979 ; 144: 174-177.
34. Wallace DJ Does hydroxychloroquine protect against clot formation in systemic lupus erythematosus? Arthritis Rheum 1997 ; 30: 1435-1436.
35. Petri M. Lupus in Baltimore: evidence-based clinical pearls from the Hopkins Lupus Cohort. Lupus 2005 ; 14: 970-973. (Pubitemid 43088273)
36. Kaiser R., Cleveland CM, Criswell LA Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009 ; 68: 238-241.
37. Tektonidou MG, Laskari K., Panagiotakos DB, Moutsopoulos HM Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009 ; 61: 29-36.
38. Ho KT, Ahn CW, Alarcon GS, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 2005 ; 44: 1303-1307.
39. Ruiz-Irastorza G., Egurbide MV, Pijoan JL, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006 ; 15: 577-583. (Pubitemid 44661744)
40. Erkan D., Yazici Y., Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002 ; 41: 924-929.
41. McCarty GA, Cason TE Use of hydroxychloroquine in antiphospholipid antibody syndrome at three academic rheumatology units over two years: improvement in antibody titer and symptom management. 7th International Congress on SLE and related conditions abstract book 2004 ; M17A (abstract).
42. Erkan D., Derksen WJ, Kaplan V., et al. Real world experience with antiphospholipid antibodies (aPL) How stable and significant are aPL?. Ann Rheum Dis 2005 ; 64: 1321-1325. (Pubitemid 41206250)
43. Colli S., Eligini S., Lalli M., et al. Statins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997 ; 17: 265-272. (Pubitemid 27098183)
44. Halcox JPJ, Deanfield JE Beyond the laboratory. Clinical implications for statin pleitropy. Circulation 2004 ; 109 (Suppl II). 42-48.
45. Baetta R., Camera M., Comparato C., et al. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in absence of lipid lowering. Arterioscler Thromb Vasc Biol 2002 ; 22: 692-698. (Pubitemid 34408755)
46. Cortellaro M., Cofrancesco E., Arbustini E., et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost 2002 ; 88: 41-47. (Pubitemid 34752265)
47. Ridker PM, Danielson E., Fonseca FA, et al. JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009 ; 373: 1175-1182.
48. Glynn RJ, Danielson E., Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009 ; 360: 1851-1861.
49. Meroni PL, Raschi E., Testoni C., et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001 ; 44: 2870-2878. (Pubitemid 34016207)
50. Ferrara DE, Liu X., Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003 ; 48: 3272-3279. (Pubitemid 37409342)
51. Ferrara DE, Swerlick R., Casper K., et al. Fluvastatin inhibits upregulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004 ; 2: 1558-1563. (Pubitemid 40186171)
52. Martínez-Martínez LA, Amigo MC, Orozco A., et al. Effect of rosuvastatin on VCAM-1 expression by HUVEC exposed to APS serum in an in vitro model. Clin Exp Rheumatol 2007 ; 25: 18-19.
53. Girardi G. Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. J Reprod Immunol 2009 ; 82: 126-131.
54. Kumar SS, Papalardo E., Jajoria P., et al. Effects of fluvastatin on prothrombotic/proinflammatory markers in patients with Antiphospholipid Syndrome. Arthritis Rheum 2008 ; 58: S172 (abstract).
55. Cuadrado MJ, Lopez-Pedrera C., Aguirre A., et al. Changes operated in protein pattern of monocytes from patients with antiphospholipid syndrome treated with statins. Arthritis Rheum 2007 ; 56: S782 (abstract).
56. Bouma B., De Groot PhG, Van Der Elsen JMH, et al. Adhesion mechanism of human B2glycoprotein-I to phospholipids based on its crystal structure. EMBO J 1999 ; 18: 5166-5174. (Pubitemid 29465567)
57. Ostertag MV, Liu X., Henderson V., Pierangeli SS A peptide that mimics the Vth region of β2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus 2006 ; 15: 358-365.
58. Ma K., Simantov R., Zhang J., et al. High affinity binding of β2glycoprotein I to human endothelial cells is mediated by Annexin II. J Biol Chem 2000 ; 275: 15541-15548. (Pubitemid 30337288)
59. Zhang J., McCrae KR Annexin A2 mediates endothelial cell activation by antiphospholipid/β2glycoprotein I antibodies. Blood 2005 ; 105: 1964-1969. (Pubitemid 40731779)
60. Romay-Penabad Z., Montiel-Manzano MG, Shilagard T., et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009 ; 114: 3074-3083.
61. Raschi E., Testoni C., Bosisio D., et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003 ; 101: 3495-3500. (Pubitemid 36857933)
62. Zhang J., Lieske K., McCrae B., McCrae K. Activation of endothelial cells by β2glycoprotein I (β2GPI) antibodies is mediated by annexin II cross linking and may involve TLR4. Blood 2004 ; 104: 83 (abstract).
63. Sorice M., Longo A., Capozzi A., et al. Anti-β2glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction involving lipid rafts. Arthritis Rheum 2007 ; 56: 2687-2697. (Pubitemid 47237287)
64. Pierangeli SS, Vega-Ostertag ME, Raschi E., et al. Toll like receptor-4 is involved in antiphospholipid-mediated thrombosis: in vivo studies. Ann Rheum Dis 2007 ; 66: 1327-1333.
65. Andersen OM, Benhayon D., Curran T., Willnow TE Differential binding of ligands to the apolipoprotein E receptor 2. Biochemistry 2003 ; 42: 9355-9364. (Pubitemid 36959243)
66. Pinson KI, Brennan J., Monkley S., et al. An LDL-receptor-related protein mediates Wnt signaling in mice. Nature 2000 ; 407: 535-538.
67. Van Lummel M., Pennings MTT, Derksen RHWM, et al. The binding site of β2glycoprotein I for apoER2 on platelets is located in Domain V. J Biol Chem 2005 ; 280: 36279-36736.
68. Lutters BCH, Derksen Rhwm, Tekelenburg WL, et al. Dimers of β2glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2. J Biol Chem 2003 ; 278: 33831-33838.
69. DeLaat B., Derksen RH, Urbanus RT, deGroot PG IgG antibodies that recognize epitope Gly40-Arg 43 in domain I of β2glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005 ; 105: 1540-1545.
70. Ioannou Y., Giles I., Lambrianides A., et al. A novel expression system of domain I of human b2glycoprotein I in Escherichia coli. BMC Biotechnol 2006 ; 6: 8.
71. Ioannou Y., Pericleous C., Giles I., et al. Binding of Antiphospholipid antibodies to discontinuous epitopes on domain I of human b2glycoprotein I. Mutation studies including residues R39 to R43. Arthritis Rheum 2007 ; 56: 280-290. (Pubitemid 46106202)
72. Ioannou Y., Romay-Penabad Z., Periclerous C., et al. In vivo inhibition of antibody-induced pathogenicity utilizing the antigenic target peptide domain I of β2glycoprotein I: proof of concept. J Thromb Haemost 2009 ; 7: 833-842.
73. Holers VM, Girardi G., Mo L., et al. C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002 ; 195: 211-220. (Pubitemid 34461265)
74. Salmon JE, Girardi G., Holers VM Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002 ; 61: 46-50. (Pubitemid 35221713)
75. Pierangeli SS, Girardi G., Vega-Ostertag ME, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005 ; 52: 2120-2124. (Pubitemid 40994335)
76. Romay-Penabad Z., Liu X., Montiel-Manzano G., et al. C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. NY Acad Sci 2007 ; 1108: 554-566. (Pubitemid 47528769)
77. Ricklin D., Lambris J. Complement-targeted therapies. Nat Biotechnol 2007 ; 25: 1265-1275.
78. Carrera-Marín AL, Romay-Penabad Z., Qu HC, et al. A C5a receptor antagonist ameliorates in vivo effects of antiphospholipid antibodies. Arthritis Rheum 2009 ; 60: s767 (abstract).
79. Girardi G., Redecha P., Salmon JE Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004 ; 10: 1222-1226. (Pubitemid 39540439)
80. Munakata Y., Saito T., Matsuda K., et al. Detection of complement-fixing antiphospholipid antibodies in association with thrombosis. Thromb Haemost 2000 ; 83: 728-731. (Pubitemid 30248522)
81. Oku K., Atsumi T., Bohgaki M., et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2008 ; 68: 1030-1035.
82. Davis WD, Brey RL Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Immunol 1992 ; 10: 455-460.
83. Youinou P., Reneaudineau Y. The antiphospholipid syndrome as a model for B-cell-induced autoimmune diseases. Thromb Res 2004 ; 114: 363-369. (Pubitemid 39422568)
84. Kahn P., Ramanujman M., Bethunaickan R., et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum 2008 ; 58: 2824-2283.
85. Akkerman A., Huang W., Wang X., et al. CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity 2004 ; 37: 445-451. (Pubitemid 40123413)
86. Erre GL, Pardini S., Faedda R., et al. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 2008 ; 17: 50-55. (Pubitemid 351487020)
87. Tenedios F., Erkan D., Lockshin MD Rituximab in the primary antiphospholipid antibody syndrome. Arthritis Rheum 2005 ; 52: 4078 (abstract).
88. Erdozain JG, Ruiz-Irastorza G., Egurbide MV, et al. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica 2004 ; 89: ECR34 (abstract).
89. Rubenstein E., Arkfeld DG, Metyas S., et al. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006 ; 33: 355-357. (Pubitemid 43209314)
90. Biasucci LM, Vitelli A., Liuzzo G., et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996 ; 94: 874-877.
91. Fisman EZ, Benderly M., Esper RJ, et al. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol 2006 ; 98: 14-18. (Pubitemid 43902673)
92. Del Papa N., Guidali L., Sala A., et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997 ; 40: 551-561. (Pubitemid 27123672)
93. Bernales I., Fullaondo A., Marin-Vidalled MJ, et al. Innate immune response gene expression profiles characterize primary antiphospholipid syndrome. Genes Immun 2008 ; 9: 38-46. (Pubitemid 351150033)
94. Salobir B., Sabovic M. Interleukin-6 and antiphospholipid antibodies in women with contraceptive-related thromboembolic disease. Obstet Gynecol 2004 ; 104: 564-570. (Pubitemid 40458846)